about
Nutritional and Nanotechnological Modulators of MicrogliaAdvanced Nanobiomaterials: Vaccines, Diagnosis and Treatment of Infectious DiseasesMitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems.Recent Advances in Subunit Vaccine CarriersThe Use of Synthetic Carriers in Malaria Vaccine DesignFrom Antigen Delivery System to Adjuvanticy: The Board Application of Nanoparticles in VaccinologyGas Vesicle Nanoparticles for Antigen DisplayCell Membrane-Coated Nanoparticles As an Emerging Antibacterial Vaccine PlatformDendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to ClinicBiodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes TargetingEndoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccinesUltradeformable Archaeosomes for Needle Free Nanovaccination with Leishmania braziliensis AntigensCombining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody ResponsesNanoparticle-allergen complexes for allergen immunotherapy.A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesControlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization.Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner.Peptide amphiphile micelles self-adjuvant group A streptococcal vaccinationM2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protectionOvercoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.A thermostable, chromatographically purified Ebola nano-VLP vaccine.Whole-animal imaging and flow cytometric techniques for analysis of antigen-specific CD8+ T cell responses after nanoparticle vaccination.Immunogenicity of Outer Membrane Proteins VirB9-1 and VirB9-2, a Novel Nanovaccine against Anaplasma marginale.Immunizing against Anogenital Cancer: HPV VaccinesPotential of nanoparticles for allergen-specific immunotherapy - use of silica nanoparticles as vaccination platform.Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice.Harnessing nanoparticles for immune modulationImmunogenicity and protective potential of a Plasmodium spp. enolase peptide displayed on archaeal gas vesicle nanoparticles.Preparation and immunogenicity of gold glyco-nanoparticles as antipneumococcal vaccine model.New prospects for a preventive HIV-1 vaccine.The Adjuvant Activity of Epimedium Polysaccharide-Propolis Flavone Liposome on Enhancing Immune Responses to Inactivated Porcine Circovirus Vaccine in Mice.Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells.A Comparison Study of iTEP Nanoparticle-Based CTL Vaccine Carriers Revealed a Surprise Relationship between the Stability and Efficiency of the Carriers.Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells.IgA response and protection following nasal vaccination of chickens with Newcastle disease virus DNA vaccine nanoencapsulated with Ag@SiO2 hollow nanoparticles.Green synthesis and evaluation of silver nanoparticles as adjuvant in rabies veterinary vaccine.Rehmannia glutinosa polysaccharide liposome as a novel strategy for stimulating an efficient immune response and their effects on dendritic cells
P2860
Q26740644-C22B56F8-9FE5-4776-AAA2-E2399B077B4FQ26744748-BA0C6810-6E8E-4F7B-9732-5F8062B32BBFQ26748776-BD969B24-E4C7-4B04-8788-677A6A3B2785Q26750929-A1F5303B-CDD9-4644-BF99-9CE52C036FC7Q26777053-C6FF4034-2C88-4E7F-8179-326A5255DBA4Q26778126-FFAC7DBD-A1CB-462B-BE98-B32E54194911Q26782563-BA3A7BAD-8670-439D-9B0E-A0CB05BBAB8EQ26784233-F58317EC-E490-4C28-B911-76DA88AF8EF0Q27023621-82794C5D-0706-4362-9168-388E67C17C12Q28072997-BD16EC76-FCFB-4605-AECC-9F81677C6736Q28084299-A6CC6003-57C3-4A11-9788-EFC5DAAB4D91Q28550483-E7345D56-832A-421A-AF94-8E36098B9653Q30358185-AB76F0C4-4460-4692-913C-0A3F398EE96DQ33710195-2E1440EB-F506-4A35-A44D-730FA61CC786Q33834985-C0A25154-42D0-4123-AEED-ADA364571B0AQ33916892-A0533B23-F927-496D-B1C0-1ABB86CA094AQ34057711-7AF6C72B-47B0-4421-8BD8-807EDF5EACF8Q34985692-C75E78DE-19B6-4B51-8410-EE71BC3A4B55Q35165017-825C3070-694F-4D58-8F74-8BB6921216A6Q35192883-C21B20A8-E7EA-485B-8D5D-6BAE63783514Q35565480-9E0E2318-8824-4EA4-AA19-5F0B062A9112Q35684362-14DE279B-60DC-4FE9-8C4F-3F0E54ECF5DCQ35853669-93108B00-200F-4A0A-A3DB-D5C46B1C02BFQ35970758-740FE106-4B27-42CA-B117-39FE4A5051D0Q35999402-5748B43C-D656-49A5-9346-C718FE594BC9Q36022468-6A9822E4-27EA-47F5-BEEF-0ED87D0686A6Q36056484-7586BD02-BE95-44B7-9C0D-9023EDED9CFBQ36079818-ACCFC40C-51AA-4C15-BEC1-B852F234CBBCQ36126206-DE5680C5-B3E3-44CE-8298-0697C03A2DDEQ36154772-8646A3BE-65CD-47CF-B361-C1183A76AA17Q36160348-A5880558-54CD-4BAB-8771-E31EA8A88FDAQ36202229-B648C513-B0E2-4A2F-89B8-9DDF4BDA967BQ36223864-55C84EB4-632D-4610-B7E6-A5927467B18CQ36285370-8310ECD4-7C78-4721-BBF1-3DF2E246A1CDQ36381340-E5483F93-3EEC-4865-BBFD-715CBC0CB070Q36723754-21FAD1ED-DCA7-493D-85E9-48D17393FD4DQ36821628-8C109CAD-218D-4990-A552-53D35D045EA2Q36893661-805A4644-5A0A-4C11-99D2-7EB04FA48462Q37152369-554AB1BB-7121-4F1C-A179-7F57311040D6Q37515726-60F39B65-C811-46EA-BA66-0345C255A615
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Nanoparticle vaccines.
@en
type
label
Nanoparticle vaccines.
@en
prefLabel
Nanoparticle vaccines.
@en
P2093
P1433
P1476
Nanoparticle vaccines.
@en
P2093
Anton P J Middelberg
Arjun Seth
Chun-Xia Zhao
Liang Zhao
Nani Wibowo
Neena Mitter
P304
P356
10.1016/J.VACCINE.2013.11.069
P407
P577
2013-12-02T00:00:00Z